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Abstract
Background: Positron Emission Tomography/computed tomography (PET/CT) is an imaging technique which has a
role in the detection and staging malignancies (both in first diagnosis and follow-up). The finding of an unexpected
region of FDG (Fluorodeoxyglucose) uptake can occur when performing whole-body FDG-PET, raising the possibility of
a second primary tumor. The aim of this study was to evaluate our experience of second primary cancer incidentally
discovered during PET/CT examination performed for pancreatic diseases, during the initial work-up or follow-up after
surgical resection.
Methods: In this study, a retrospective evaluation of a prospectively collected data base was performed. Three hundred
ninety- nine patients with pancreatic pathology were evaluated by whole body PET/CT imaging from January 2004 to
December 2014. Among them, 348 patients were scanned before surgical resection and 51 during the course of their
follow-up (pancreatic cancer). Median follow-up time was 29 months (range 14-124).
Results: Fifty-six patients (14%) had incidental uptake of FDG in their organs: 31 patients had focal uptake and 25 showed
diffuse with or without focal uptake. All patients with focal uptake were investigated, and invasive malignancy
was diagnosed in 22 patients: 14 colon, 4 lung, 1 larynx, 1 urothelial, 1 breast cancer, and 1 colon metastasis from
pancreatic cancer. Twenty patients underwent resection, and 6 endoscopic removal of colonic polyps. Three patients
were not operated for advanced disease, and two patients did not show any pathology (PET/CT false positive). Of the
10 patients investigated for diffuse uptake, no malignancy was found; none of these patients developed a second
cancer during the follow-up.
Conclusions: As in other malignancies, unexpected FDG uptake can occur in patients having PET/CT investigation for
pancreatic diseases. Focal uptake is likely to be a malignancy and deserves further investigations, although the stage
and the poor prognosis of primary pancreatic cancer should be kept in mind. Some selected patients may benefit from
the aggressive treatment of incidental lesions and show survival benefit.
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Background
Positron Emission Tomography/computed tomography
(PET/CT) is an imaging technique which has a role in
the detection of malignancies and in cancer staging
(both in first diagnosis and follow-up) [1, 2], including
pancreatic neoplasms [3]. The finding of an unexpected
region of FDG uptake can occur when performing whole-
body FDG-PET; this raises the possibility of a second pri-
mary tumor [4]. In the past decade, incidental cancer has
been detected by PET/CT in asymptomatic patients [5],
patients with head neck cancer [6], oesophagogastric
malignancies [7], lymphoma [8], and lung cancer [9].
Informations regarding PET/CT incidental cancer in
patients with pancreatic neoplasms are still lacking. Aim
of this study was to assess the frequency and significance
of incidental findings reported by PET/CT scans in
patients investigated for pancreatic lesions, both benign
and malignant.
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Methods
Patients who underwent PET/CT examination for staging
or follow-up after resection of pancreatic tumors observed
in our Department from January 2004 to December 2014,
were identified from a prospectively collected database.
The scans were reviewed and any incidental findings
recorded. One person (SB) assessed all PET/CT reports.
An incidental finding was defined as a significant area of
FDG uptake in a site unlikely to be related to the pancre-
atic neoplasm. FDG uptake was described according to
focal or diffuse pattern assessed by the nuclear medicine
physician. Clinical, radiographic, endoscopic, surgical and
pathological records, and follow-up imaging were used
as evaluation of incidental PET findings. A validation of
the diagnosis was based on the pathologic findings of a
resected specimen, biopsy examination, or follow-up.
When an extrapancreatic or focal uptake of 18-FDG
was detected, an additional diagnostic work-up was
performed. All suspected lesions underwent histological
confirmation. 18F-FDG PET scans were performed
using standard clinical protocols by a hybrid system
(Biograph Sensation 16, Siemens, provided with a multislice
CT and LSO crystals). A minimum fasting time of 6 h was
prescribed and blood glucose levels less than 120 mg/dl
before intravenous injection of a weight-based amount
of 18-FDG (37 MBq/10 kg) were obtained. The CT
scans were performed without oral and/or intravenous
contrast medium. Cross-sections for attenuation correction
of the emission images (when the PET tomograph without
CT was used) were obtained with two transmission scans
of the abdomen by 68 Ge/68 Ga rod sources before the
administration of 18-FDG. When using the hybrid system,
CT scan was done with a kCp of 120 and weight-based
amperage of 120 mAs. PET scan (for both tomographs)
began 90 min after the tracer’s injection acquiring 2 beds
(16 cm each) to cover upper abdomen area. Coronal,
sagittal and transaxial sections were obtained for visual
analysis. In the suspected neoplastic areas, a quantitative
analysis was performed through the calculation of the
maximum standardized uptake value (SUVmax, SUV =
tissue tracer concentration/injected dose/body weight)
which was analyzed by placing a circular region of interest
(on transaxial sections) over the area of maximal focal
18-FDG uptake. We established a SUVmax cut-off of 2.5
or greater according to our previous experience. The PET
scan was interpreted by a single observer (S.B.) without
knowledge of the CT scan results.
Results
A total of 399 patients underwent PET/CT imaging during
the study period: 348 in the initial work-up for pancreatic
neoplasm, and 51 in the course of follow-up after resection
for pancreatic cancer. Incidental FDG uptake was identified
in 56 patients (14%): in these patients, pancreatic neoplasms
included ductal adenocarcinoma (n = 32), intraductal
papillary mucinous neoplasms (IPMNs, n = 21), cystic neo-
plasms (two mucinous tumors and 1 solid-pseudopapillary
tumor). Forty-five patients underwent PET/CT at initial
stage and 11 during the course of their follow-up after
resection of pancreatic cancer. Thirty-one patients (55%)
had focal uptake, while 25 (45%) showed diffuse with or
without focal uptake. Focal uptake was observed in the
colon (n = 21), lung (n = 4), rectum (n = 2), larynx (n = 1),
urether (n = 1), breast (n = 1), duodenum (n = 1) (Table 1).
Diffuse with or without focal uptake was observed in the
colon (n = 20), rectum (n = 2), thyroid (n = 2), oesophagus
Table 1 Site of incidental findings, results of investigation, treatment and outcome of patients with PET/CT extra-pancreatic focal
uptake of the radiotracer
Site Total Number
of Patients
Pathology Number
of patients
Treatment Outcome
N° A / D (mo)
Colon 19 Adenocarcinoma 14 Colectomy 13 D
1 A (61)
Pancreatic cancer metastasis 1 CT 1 D (8)
HGD 4 ER 4 D
Rectum 2 HGD 2 ER 1 D
1 A (74)
Lung 4 Adenocarcinoma 3 Lobectomy 3 D
1 CT 1 D (13)
Breast 1 Ductal Carcinoma 1 CT 1 D (7)
Ureter 1 Urothelial Cancer 1 Nephrectomy 1 D (21)
Duodenum 1 HGD 1 PD 1 A (72)
Larynx 1 Laryngeal Cancer 1 Laryngectomy 1 D (27)
D dead, A alive, CT chemotherapy, ER endoscopic resection, PD pancreaticoduodenectomy, HGD high grade dysplasia
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(n = 1), stomach (n = 1) (Table 2). The colon was the most
common site of FDG uptake in all groups (Figs. 1, 2). All
patients with focal uptake were investigated with colonos-
copy (n = 23), contrast-enhanced CT (n = 5), gastroscopy
(n = 1), mammography (n = 1), laryngoscopy (n = 1). Investi-
gations were performed in 10 patients with diffuse uptake
(5 colonoscopy, 2 gastroscopy, 2 ultrasonography and fine-
needle aspiration, 1 sigmoidoscopy).
Of the 31 patients investigated for focal FDG uptake
(19 patients with primary malignant tumors and 12
benign pancreatic neoplasms), invasive malignancy was
diagnosed in 22 patients: 14 colon adenocarcinoma, 4
Table 2 Site of incidental findings, results of investigation, reasons of non investigation of patients with pancreatic tumors who
underwent PET/CT with diffuse uptake of the radiotracer
Site Total Number
of Patients
Investigated Reason of Non Investigation
N° Pathology N° Reason
Oesophagus 1 1 Oesophagitis – –
Stomach 1 1 Gastritis – –
Colon 20 5 1 Hyperplastic Polyps 8 Physiological uptake
7 Advanced Disease
Rectum 2 1 Proctitis – –
Thyroid 2 2 Benign Goiter – –
Fig. 1 PET/CT incidental detection of cancer of the ascending colon associated with branch-type IPMN of the pancreatic head (PET negative)
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lung adenocarcinoma (Fig. 3), 1 cancer of the larynx, 1
urothelial cancer (Fig. 4), 1 breast cancer, and 1 colon
metastasis from pancreatic cancer. Among the remaining
9 patients, 7 showed colonic (n = 6) or duodenal (n = 1)
polyps with high-grade dysplasia, and two patients did not
show any pathology. Fourteen patients underwent colec-
tomy, 6 endoscopic removal of colonic polyps, 3 lung
lobectomy, 1 laryngectomy, 1 pancreaticoduodenectomy,
and 1 nephrectomy. Five patients did not undergo surgery:
three for advanced disease (1 lung cancer, 1 breast cancer,
and 1 pancreatic cancer metastasis), and two for not
evidence of disease (false positive). Among patients
with pathological uptake of FDG during initial work-up
for pancreatic cancer (n = 7 patients), in 5 patients
detection of second tumor changed the operative manage-
ment and a colectomy was associated with the pancreatic
resection. The other two patients did not undergo pan-
creatic resection for advanced cancer. After a median
follow-up of 29 months (range 14-96 months), 2 patients
investigated for pancreatic cancer are alive and free of
disease, 4 and 5 years after resection of lung cancer and
colon cancer, respectively. The remaining patients died
of progression of disease, with a median overall survival
of 20 months (range 5-96 months), with 5 long survivors
(survival > 60 months) .
Among the 12 patients investigated for benign pancreatic
disease (9 IPMNs and 3 cystadenomas), 8 patients are alive
and disease-free (median survival time 48 months) while 2
patients died for colon cancer (n = 1) and urothelial cancer
(n = 1) 37 and 16 months after surgery, respectively. The
remaining 2 patients died for causes unrelated to cancer.
Of the 10 patients investigated for diffuse uptake,
hyperplastic colonic polyps were detected in 1 patient,
proctitis in 1, gastritis in 1, oesophagitis in 1, thyroid
goiter in 2, no abnormality in the remaining 4 patients
(Table 2). None of these patients developed a second
cancer during the entire follow-up. Quantitative analysis
did not show significant difference between lesions with
focal uptake (mean SUV = 6.4, range 3.0-12.5) and diffuse
uptake (mean SUV 5.1, range 2.5-10.0).
A total of 51 patients underwent PET/CT during the
follow-up after resection of pancreatic cancer. Eleven
patients showed extrapancreatic focal uptake of FDG
and 9 had resection of confirmed second cancer; one
patient is alive 61 months after operation, while 8 patients
died for recurrent pancreatic or colon cancer with a median
survival time of 41 months (range 13-118 months). The
remaining two patients did not have evidence of disease
(colon) and are still alive and well after 1 and 3 years,
respectively (Table 3).
Discussion
FDG-PET offers the unique opportunity to provide not
only whole-body images, but also metabolic or functional
informations regarding the tumor tissue. Moreover, the
widespread availability of this imaging technique led to
increasing number of incidental findings: this necessarily
suggest further investigations in order to exclude malig-
nancies. As previously reported by other studies dealing
with PET/CT in different malignancies, we have observed
an increasing number of extrapancreatic FDG uptake in
patients with pancreatic neoplasms. So, we evaluated our
experience of incidental findings of PET/CT performed for
patients with neoplasms of the pancreas: to our knowledge
this is the first study dedicated to this specific topic. An
incidental finding was detected in 14% of the patients in
our study, and it was further investigated in 72% of cases
(all with focal and 10 out of 25 patients with diffuse
uptake). Second malignant or premalignant lesions were
confirmed in all but one patient who showed PET/CT with
focal uptake: the remaining patient with a focal FDG
uptake had a colonic metastasis from pancreatic cancer
confirmed by pathologic examination. The number of
incidental findings in our study appears higher than that
reported by other authors [10, 11] but much greater inci-
dence (more than 20%) has been reported for other types
of primary neoplasms [9, 12].
Most of our PET/CT incidental findings were localized
in the large bowel, in according with previous studies
Fig. 2 PET/CT incidental detection of cancer of the sigmoid colon
39 months after pancreatico-duodenectomy for pancreatic cancer
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including patients with different primary tumors [13–15].
In our study a malignant or premalignant lesion was
detected in 74% of patients who underwent endoscopy. A
confirmed pathologic lesion was obtained in all but two
patients with focal FDG uptake, while none of the patients
investigated for diffuse FDG uptake showed unexpected
tumors. This finding outlines the concept that when a
focal uptake of FDG is detected, a high suspicion of
malignancy is suggested, and further investigations are
necessary [16–18]. One could argue that detection of a
second tumor in patients with such an aggressive disease
as pancreatic cancer does not modify the poor prognosis,
and it is without a clinical significance. However, in our
experience, some patients who underwent resection of
a second neoplasm incidentally detected by PET/CT,
showed prolonged survival: this is particularly true for
lesions incidentally detected in the follow-up of patients
without recurrence after resection of pancreatic cancer.
So, as we previously reported [19], PET/CT is useful not
only for the staging of pancreatic malignancy, but also for
the postoperative surveillance of resected pancreatic cancer.
Moreover, it has been reported that IPMNs are at risk of
association with extra-pancreatic malignancies [20, 21], but
contrasting results are also suggested [22, 23]. In our study,
21 patients with benign IPMNs showed extra-pancreatic
PET/CT incidental findings: in 11 patients a focal uptake of
the radiotracer was evident, and a second malignancy was
resected in 9.
In our Center, after an initial period when PET/CT
was performed (whenever possible) in almost all patients
with pancreatic cancer, we now perform it to stage
resectable cancer and, when indicated, during the follow-
Fig. 3 PET/CT incidental detection of left pulmonary adenocarcinoma 31 months after distal pancreatectomy for pancreatic cancer
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up of resected patients. Moreover, we think that PET/CT
can be an useful tool also during follow-up of selected pa-
tients with IPMNs. On the contrary, we have observed
that PET/CT is unlikely to modify the management of
patients with metastatic pancreatic cancer.
Conclusions
As in other tumors, our study reveals that unexpected
FDG uptake is frequent in patients having PET/CT
investigation for pancreatic neoplasms. Focal uptake is
likely to be a malignancy and deserves accurate examin-
ation, although the stage and the poor prognosis of primary
cancer should be kept in mind. Some selected patients
(with benign IPMN, or in follow-up after resection of pan-
creatic cancer) may benefit from the aggressive treatment
of incidental lesions and show survival benefit.
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